Chernysheva Natalia B, Maksimenko Anna S, Andreyanov Fedor A, Kislyi Victor P, Strelenko Yuri A, Khrustalev Victor N, Semenova Marina N, Semenov Victor V
N. D. Zelinsky Institute of Organic Chemistry RAS, 47 Leninsky Prospect, 119991, Moscow, Russian Federation.
N. D. Zelinsky Institute of Organic Chemistry RAS, 47 Leninsky Prospect, 119991, Moscow, Russian Federation; D. I. Mendeleev University of Chemical Technology of Russia, 9 Miusskaya pl., 125047, Moscow, Russian Federation.
Eur J Med Chem. 2018 Feb 25;146:511-518. doi: 10.1016/j.ejmech.2018.01.070. Epub 2018 Jan 31.
4,5-Diarylisoxazoles are potent antiproliferative tubulin-targeting agents. Their isomeric 3,4-diaryl-5-unsubstituted isoxazoles are hardly accessible. The synthesis of 3,4-diaryl-5-unsubstituted isoxazoles 13 was designed based on a condensation of arylbenzaldehydes, arylnitromethanes, and ethoxycarbonylmethylpyridinium bromide followed by a selective one-step transformation of intermediate 3,4-diaryl-5-ethoxycarbonyl-4,5-dihydroisoxazole 2-oxides 8. The orientation of aryl rings in relation to isoxazole heterocycle was confirmed by X-ray crystallography. Targeted compounds were evaluated for antimitotic microtubule destabilizing activity using a phenotypic sea urchin embryo assay. 3-(4-Methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)isoxazole 13e and 13h with a single methoxy substituent were the most potent. Compound 13e showed strong cytotoxicity in NCI60 screen with GI for NCI-H522 human lung cancer cell line of 0.023 μM.
4,5-二芳基异恶唑是有效的抗增殖微管靶向剂。它们的异构体3,4-二芳基-5-未取代异恶唑很难获得。3,4-二芳基-5-未取代异恶唑13的合成基于芳基苯甲醛、芳基硝基甲烷和乙氧基羰基甲基吡啶溴化物的缩合反应,随后对中间体3,4-二芳基-5-乙氧基羰基-4,5-二氢异恶唑2-氧化物8进行选择性一步转化。通过X射线晶体学确定了芳基环相对于异恶唑杂环的取向。使用表型海胆胚胎试验评估目标化合物的抗有丝分裂微管去稳定活性。具有单个甲氧基取代基的3-(4-甲氧基苯基)-4-(3,4,5-三甲氧基苯基)异恶唑13e和13h活性最强。化合物13e在NCI60筛选中对NCI-H522人肺癌细胞系表现出强烈的细胞毒性,其GI为0.023μM。